Cargando…

A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia

BACKGROUND: Resistance to therapy and a poor outcome characterize relapsed or refractory acute myeloid leukemia (AML). There is a clear need for additional palliative approaches with acceptable toxicities. Vincristine sulfate liposome injection (VSLI) confers enhanced pharmacokinetics and activity w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seegars, Mary Beth, Woods, Ryan, Ellis, Leslie R., Bhave, Rupali Roy, Howard, Dianna S., Manuel, Megan, Dralle, Sarah, Lyerly, Susan, Powell, Bayard L., Pardee, Timothy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891907/ https://www.ncbi.nlm.nih.gov/pubmed/33643502 http://dx.doi.org/10.14740/jh771

Ejemplares similares

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Marqibo(®) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
por: Silverman, Jeffrey A., et al.
Publicado: (2012)

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia
por: Raj, Trisha A Soosay, et al.
Publicado: (2013)

Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
por: Davis, Tyler, et al.
Publicado: (2013)

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia [Corrigendum]
Publicado: (2013)

The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate
por: Zhang, Jing, et al.
Publicado: (2016)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma
por: Yang, Fen, et al.
Publicado: (2018)

Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?
por: Chadha, Juskaran, et al.
Publicado: (2019)

The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study
por: Yates, Samuel J., et al.
Publicado: (2020)

Conventional-Vincristine Sulfate vs. Modified Protocol of Vincristine Sulfate and L-Asparaginase in Canine Transmissible Venereal Tumor
por: Setthawongsin, Chanokchon, et al.
Publicado: (2019)

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022)

Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: a light-responsive nanocarrier with enhanced antitumor efficiency
por: Liu, Ying, et al.
Publicado: (2015)

Development and characteristics of novel sonosensitive liposomes for vincristine bitartrate
por: Lin, Wen, et al.
Publicado: (2019)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
por: Yao, Han, et al.
Publicado: (2023)

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study
por: Ollila, Thomas, et al.
Publicado: (2022)

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
por: Noble, Charles O., et al.
Publicado: (2009)

Development of a stable single-vial liposomal formulation for vincristine
por: Mao, Wenxue, et al.
Publicado: (2019)

Vincristine liposomes with smaller particle size have stronger diffusion ability in tumor and improve tumor accumulation of vincristine significantly
por: Ma, Siyu, et al.
Publicado: (2017)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
por: van Eijkelenburg, Natasha K.A., et al.
Publicado: (2018)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Correction to “Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy”
por: Wang, Chenyu, et al.
Publicado: (2022)

PB1850: MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH CLAG REGIMEN IN REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (NON-M3)
por: Wan, Kai, et al.
Publicado: (2023)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Effects of Vincristine Sulfate in Dogs with Transmissible Venereal Tumor (TVT)
por: HANTRAKUL, Supannika, et al.
Publicado: (2014)

Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma
por: Zhang, Yue, et al.
Publicado: (2017)

Epigallocatechin‐3‐gallate sensitises multidrug‐resistant oral carcinoma xenografts to vincristine sulfate
por: Chen, Li, et al.
Publicado: (2020)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
por: Shah, Jatin J, et al.
Publicado: (2009)

Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes
por: Xu, Yuzhen, et al.
Publicado: (2015)

Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination
por: Saito, Kei, et al.
Publicado: (2021)

B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
por: Goswami, Meghali, et al.
Publicado: (2020)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
por: Ma, Jiale, et al.
Publicado: (2021)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
por: Webb, M. S., et al.
Publicado: (1995)

Application of vincristine-loaded platelet therapy in three dogs with refractory immune-mediated thrombocytopenia
por: Park, Hyung-Jin, et al.
Publicado: (2015)

The hepatoprotective and antioxidative effect of saffron stigma alcoholic extract against vincristine sulfate induced toxicity in rats
por: HARCHEGANI, Asghar Beigi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pd6hqkacbct3egcolmln5uq88e